The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
BACKGROUND
Despite considerable efforts, a suitable vaccine against Onchocerca volvulus infection has remained elusive. Herein, we report on the use of molecular tools to identify and characterize O. volvulus antigens that are possibly associated with the development of concomitant immunity in onchocerciasis.


RESULTS
Third-stage larvae (L3) and molting L3 (mL3) O. volvulus stage-specific cDNA libraries were screened with a pool of sera from chronically infected patients who had likely developed such immunity. The 87 immunoreactive clones isolated were grouped into 20 distinct proteins of which 12 had already been cloned and/or characterized before and 4 had been proven to be protective in a small O. volvulus animal model. One of these, onchocystatin (Ov-CPI-2), a previously characterized O. volvulus cysteine proteinase inhibitor was, overall, the most abundant clone recognized by the immune sera in both the L3 and mL3 cDNA libraries. To further characterize its association with protective immunity, we measured the IgG subclass and IgE class specific responses to the antigen in putatively immune (PI) and infected (INF) individuals living in a hyperendemic area in Cameroon. It appeared that both groups had similar IgG3 and IgE responses to the antigen, but the INF had significantly higher IgG1 and IgG4 responses than the PI individuals (p<0.05). In the INF group, the IgG3 levels increased significantly with the age of the infected individuals (r = 0.241; p<0.01). The IgG1 responses in the INF were high regardless of age. Notably, culturing L3 in vitro in the presence of anti-Ov-CPI-2 monospecific human antibodies and naïve neutrophils resulted in almost complete inhibition of molting of L3 to L4 and to cytotoxicity to the larvae.


CONCLUSIONS
These results add to the knowledge of protective immunity in onchocerciasis and support the possible involvement of anti-Ov-CPI-2 IgG1 and/or IgG3 cytophilic antibodies in the development of protective immunity in the PI and the INF. The results further support the consideration of Ov-CPI-2 as a leading target for an anti-L3 vaccine.
Cho-Ngwa
Fidelis
F
Laboratory of Molecular Parasitology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, United States of America. chongwa_ub@yahoo.co.uk
Liu
Jing
J
Lustigman
Sara
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000375:Aging / Q000276:immunology*; D000818:Animals; D000909:Antibodies, Helminth / Q000097:blood* / Q000276:immunology*; D000947:Antigens, Helminth / Q000276:immunology*; D002163:Cameroon; D002648:Child; D002675:Child, Preschool; D015853:Cysteine Proteinase Inhibitors / Q000276:immunology*; D005260:Female; D015723:Gene Library; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007814:Larva / Q000201:enzymology / Q000276:immunology; D008297:Male; D008875:Middle Aged; D017181:Onchocerca volvulus / Q000201:enzymology / Q000276:immunology*; D009855:Onchocerciasis / Q000276:immunology* / Q000517:prevention & control; D055815:Young Adult
D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D015853:Cysteine Proteinase Inhibitors; D007074:Immunoglobulin G; D007073:Immunoglobulin E
J Biol Chem. 1996 Nov 22;271(47):30181-9
8939969
Mol Biochem Parasitol. 2000 Feb 25;106(1):187-95
10743624
Mol Biochem Parasitol. 1998 Mar 15;91(2):221-35
9566516
Exp Parasitol. 1993 Dec;77(4):414-24
8253155
Infect Immun. 2001 Jan;69(1):262-70
11119514
Mol Biochem Parasitol. 1991 Mar;45(1):65-75
2052041
J Parasitol. 2006 Feb;92(1):41-5
16629313
Trends Parasitol. 2002 Mar;18(3):135-41
11854092
Infect Immun. 2000 Jun;68(6):3491-501
10816503
Int J Parasitol. 2002 Feb;32(2):171-8
11812494
Infect Immun. 2003 May;71(5):2422-9
12704112
Mol Biochem Parasitol. 1992 Jan;50(1):79-93
1542318
Int J Parasitol. 2003 Sep 30;33(11):1161-71
13678632
J Immunol. 1991 Jun 1;146(11):4001-10
2033268
Exp Parasitol. 2000 Mar;94(3):158-62
10831380
J Infect Dis. 1995 Jun;171(6):1586-92
7539474
Parasite Immunol. 1991 May;13(3):277-90
1852475
Infect Immun. 2000 Jul;68(7):4174-9
10858234
Mol Biochem Parasitol. 1997 Dec 1;90(1):55-68
9497032
Infect Immun. 2000 Apr;68(4):1905-11
10722581
Trop Med Parasitol. 1994 Dec;45(4):331-5
7716398
Mol Biochem Parasitol. 2004 Apr;134(2):213-24
15003841
Infect Immun. 2002 Feb;70(2):851-8
11796620
Parasite Immunol. 1998 Jan;20(1):9-17
9491413
Exp Parasitol. 1995 Aug;81(1):9-19
7628571
Parasite Immunol. 2002 May;24(5):253-62
12060319
Adv Cancer Res. 1990;54:319-32
2105004
J Immunol. 1994 Jan 15;152(2):735-42
8283048
Tropenmed Parasitol. 1983 Mar;34(1):54-60
6682581
J Biol Chem. 1992 Aug 25;267(24):17339-46
1512269
Trans R Soc Trop Med Hyg. 1968;62(1):22-8
5639533
Exp Parasitol. 1995 Dec;81(4):445-52
8542985
Mol Biochem Parasitol. 2004 Dec;138(2):165-70
15555728
Mol Biochem Parasitol. 1994 Jun;65(2):305-15
7969271
Exp Parasitol. 2002 Mar;100(3):143-9
12173398
Microbes Infect. 2000 Sep;2(11):1363-71
11018453
Infect Immun. 2002 Jun;70(6):2796-804
12010965